摘要
Abstract
OBJECTIVE:To probe into the effects of ceftriaxone sodium combined with azithromycin on serum inflammatory factor levels and positive rate of drug-resistant gene in children with refractory Mycoplasma pneumoniae pneumonia (RMPP). METHODS:148 children with RMPP admitted into Children's Hospital Affiliated of Zhengzhou University from Feb. 2015 to Feb. 2018 were according to admission order grouping, single number as the observation group, double number as the control group, with 74 cases in each. The observation group was given ceftriaxone sodium combined with azithromycin, while the control group was treated with azithromycin alone. The clinical efficacy, serum inflammatory factor levels [interleukin-6 (IL-6), interleukin-8 (IL-8) and tumor necrosis factor (TNF-α) ], positive rate of drug-resistant gene and incidences of adverse drug reactions of two groups were observed. RESULTS:The total effective rate of observation was 95.95％ (71/74), which was significantly higher than that of the control group (86.49％, 64/74), with statistically significant difference (P＜0.05); after treatment, the IL-6, IL-8 and TNF-α levels of observation group were significantly lower than those of the control group, with statistically significant differences (P＜0.05); the positive rates of drug-resistant gene of observation group and control group were respectively 6.76％ (5/74) and 8.11％ (8/74), the difference had no statistical significance (P＞0.05); the incidences of adverse drug reactions of observation group and control group were respectively 5.41％ (4/74) and 4.05％ (3/74), the difference had no statistical significance (P＞0.05). CONCLUSIONS:The efficacy of ceftriaxone sodium combined with azithromycin in treatment of RMPP is remarkable, which can reduce the inflammatory factor levels and inhibit inflammatory reaction, safe and reliable without increasing bacterial resistance and adverse reactions.关键词
阿奇霉素/头孢曲松钠/难治性肺炎支原体肺炎/血清炎性因子Key words
Azithromycin/Ceftriaxone sodium/Refractory mycoplasma pneumoniae pneumonia/Serum inflammatory factor分类
医药卫生
